Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZHER2-ABD-MMAF
- Development stage
- Preclinical
- Lead developer
- KTH Royal Institute of Technology
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
ZHER2-ABD-MMAF (also referred to as ZHER2-ABD-mcMMAF) is an experimental, preclinical-stage affibody-drug conjugate (AffiDC) designed for the targeted treatment of HER2-overexpressing malignancies, such as ovarian cancer. It consists of a human epidermal growth factor receptor 2 (HER2)-targeting affibody molecule (ZHER2:2891) fused to an albumin-binding domain (ABD) for in vivo half-life extension, and conjugated to the highly potent cytotoxic payload monomethyl auristatin F (MMAF) via a non-cleavable maleimidocaproyl (mc) linker. By binding to serum albumin, the ABD prolongs the circulation time of the conjugate. Upon binding to HER2 on cancer cells, the conjugate is internalized, and the MMAF payload is released to inhibit tubulin polymerization, leading to cell cycle arrest and apoptosis. Preclinical studies conducted by researchers at Uppsala University and KTH Royal Institute of Technology have demonstrated that ZHER2-ABD-MMAF exhibits strong anti-tumor efficacy and complete tumor regression in mouse models of HER2-positive ovarian cancer.
- Other names
- ZHER2:2891-ABD-MMAFZHER2:2891-ABD-mcMMAF
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ZHER2-ABD-MMAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZHER2-ABD-MMAF.